更新于：2024-04-05
CYP-001
更新于：2024-04-05
概要
基本信息
非在研机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
关联
4
项与 CYP-001 相关的临床试验A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination With Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease
This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD. Severity of GvHD will be assessed at screening and throughout the study using Mount Sinai Acute GvHD International Consortium (MAGIC) guidelines. Eligible subjects will be randomized to receive either CYP-001 IV infusion on Days 0 and 4 or placebo on the same days. All subjects will receive ongoing CS therapy as appropriate per institutional guidelines. Subjects will have study visits up to Day 100 during the Primary Evaluation Period. During the Follow-Up Period, subjects will have study visits up to 24 months.
开始日期2024-03-04 |
申办/合作机构 |
A pilot, open-label, randomised controlled clinical trial to investigate early efficacy of CYP-001 in adults admitted to intensive care with respiratory failure (due to COVID-19 or another underlying condition).
开始日期2021-05-22 |
申办/合作机构 |
A Pilot, Open-label, Randomised Controlled Clinical Trial to Investigate Early Efficacy of CYP-001 in Adults Admitted to Intensive Care With Respiratory Failure
This is a pilot, multi-centre, open-label randomised controlled study to assess the early efficacy of intravenous (IV) administration of CYP-001 in adults admitted to an intensive care unit (ICU) with respiratory failure
开始日期2020-08-24 |
申办/合作机构 |
100 项与 CYP-001 相关的临床结果
登录后查看更多信息
100 项与 CYP-001 相关的转化医学
登录后查看更多信息
100 项与 CYP-001 相关的专利（医药）
登录后查看更多信息
2
项与 CYP-001 相关的文献（医药）2020-12-01·Carbohydrate polymers1区 · 化学
Structural characteristics of a mannoglucan isolated from Chinese yam and its treatment effects against gut microbiota dysbiosis and DSS-induced colitis in mice
1区 · 化学
Article
作者: Li, Pan ; Xiao, Jie ; Ren, Yunhong ; Du, Bing ; Xiao, Nan ; Chen, Yanlan ; Huang, Jianzhao ; Zeng, Liping ; Xu, Yanan
A water-soluble polysaccharide named CYP-1 was isolated from Chinese yam. CYP-1 was characterized as a mannoglucan having a backbone consisting predominately of 1,4-α-linked Glcp branched at O-2, O-3, and O-6 position by t-α-linked Manp with a molecular weight of 2.86 kDa. CYP-1 could inhibit the overproduction of pro-inflammatory cytokines (such as TNF-α and IL-1β) in LPS-induced RAW 264.7 cells and DSS-induced colitis mice. Oral administration of CYP-1 dramatically alleviated colonic pathological damage, suppressed the activation of colonic inflammatory signaling pathways (such as NF-κB and NLRP3 inflammasome), recovered the mRNA expression of junctional proteins (such as ZO-1, claudin-1, occludin, and connexin-43), and modulated the gut microbiota by decreasing the abundances of Alistipes, Helicobacter, and an unidentified Enterobacteriaceae, in DSS-induced colitis mice. Overall, the present study elucidated that a new polysaccharide structure CYP-1 from Chinese yam and its therapeutic potential as a prebiotic for the prevention of inflammatory bowel disease.
2020-11-01·Nature medicine1区 · 医学
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study
1区 · 医学
Article
作者: Hei, Derek ; Uenishi, Gene I ; Drier, Diana ; Griffin, James E ; Larson, Laurie S ; Radia, Rohini ; Yeung, David T ; Gilleece, Maria H ; Bloor, Adrian J C ; Kelly, Kilian ; Slukvin, Igor ; Patel, Amit ; Rasko, John E J
The therapeutic potential of donor-derived mesenchymal stromal cells (MSCs) has been investigated in diverse diseases1, including steroid-resistant acute graft versus host disease (SR-aGvHD)2. However, conventional manufacturing approaches are hampered by challenges with scalability and interdonor variability, and clinical trials have shown inconsistent outcomes3,4. Induced pluripotent stem cells (iPSCs) have the potential to overcome these challenges, due to their capacity for multilineage differentiation and indefinite proliferation5,6. Nonetheless, human clinical trials of iPSC-derived cells have not previously been completed. CYP-001 (iPSC-derived MSCs) is produced using an optimized, good manufacturing practice (GMP)-compliant manufacturing process. We conducted a phase 1, open-label clinical trial (no. NCT02923375) in subjects with SR-aGvHD. Sixteen subjects were screened and sequentially assigned to cohort A or cohort B (n = 8 per group). One subject in cohort B withdrew before receiving CYP-001 and was excluded from analysis. All other subjects received intravenous infusions of CYP-001 on days 0 and 7, at a dose level of either 1 × 106 cells per kg body weight, to a maximum of 1 × 108 cells per infusion (cohort A), or 2 × 106 cells per kg body weight, to a maximum dose of 2 × 108 cells per infusion (cohort B). The primary objective was to assess the safety and tolerability of CYP-001, while the secondary objectives were to evaluate efficacy based on the proportion of participants who showed a complete response (CR), overall response (OR) and overall survival (OS) by days 28/100. CYP-001 was safe and well tolerated. No serious adverse events were assessed as related to CYP-001. OR, CR and OS rates by day 100 were 86.7, 53.3 and 86.7%, respectively. The therapeutic application of iPSC-derived MSCs may now be explored in diverse inflammatory and immune-mediated diseases.
14
项与 CYP-001 相关的新闻（医药）2024-03-09
·药明康德
▎药明康德内容团队编辑近期，全球细胞和基因疗法（CGT）领域迎来系列进展。由Mustang Bio和City of Hope联合开发的CAR-T疗法MB-101在治疗复发或难治性恶性胶质瘤的1期临床试验中表现出良好的安全性，1位获得完全缓解的胶质母细胞瘤患者已经无癌超过66个月。Iovance Biotherapeutics公司宣布，美国FDA许可该公司继续进行注册性临床试验IOV-LUN-202，评估其肿瘤浸润淋巴细胞（TIL）疗法LN-145治疗非小细胞肺癌（NSCLC）的效果。本文将节选其中部分重要进展做简单介绍，仅供读者参阅。图片来源：123RF———✦研发进展✦———◇Mustang Bio和City of Hope宣布，双方联合开发的CAR-T细胞疗法MB-101治疗复发或难治性恶性胶质瘤，包括胶质母细胞瘤患者的1期临床数据已发表于Nature Medicine，这些数据展示了MB-101的良好安全性和临床活性，50%接受治疗的患者疾病稳定。MB-101是一款靶向IL-13受体α2（IL-13Rα2）抗原的CAR-T疗法。使用CAR-T疗法治疗脑瘤的一个主要挑战是CAR-T疗法难以穿过血脑屏障。City of Hope研究人员的策略是直接将CAR-T疗法注射到大脑肿瘤中（ICT），以及将CAR-T细胞注射到脑室中（ICV），让脑脊液携带它们到肿瘤病灶。试验结果显示：50%（29/58）接受治疗的患者在至少两个月内获得病情稳定或更好结果。这些患者都接受过大量治疗，属于难治类型。其中有两例部分缓解、一例完全缓解（CR），另一名患者通过同情用药渠道追加一次额外的CAR-T细胞治疗周期后也获得完全缓解。其中一名获得完全缓解的患者已经持续5年无癌。在使用ICT/ICV双重给药的优化治疗方案，并输注优化生产工艺制造的CAR-T疗法的患者亚群中，中位总生存期达到10.2个月，优于复发性GBM患者预期的6个月。◇Iovance Biotherapeutics公司宣布，美国FDA许可该公司继续进行关键性临床试验IOV-LUN-202，评估TIL疗法LN-145治疗晚期经治NSCLC患者的安全性和疗效。该公司的TIL疗法Amtagvi在2月16日获FDA加速批准上市，用于治疗晚期黑色素瘤患者。这是首款获批的TIL疗法，也是首款获批治疗实体瘤的T细胞疗法，是细胞疗法的又一里程碑。IOV-LUN-202试验的初步数据显示一次TIL治疗可提供潜在获益，包括比现有2线化疗可能更持久的缓解。在2023年11月的数据分析显示在确认获得缓解的患者中，71%的患者缓解持续时间超过6个月。◇A2 Biotherapeutics公司宣布，美国FDA已授予该公司开发的潜在“first-in-class”逻辑门控细胞疗法A2B530孤儿药资格，用于治疗肿瘤细胞表达CEA抗原，并且HLA-A*02表达缺失的结直肠癌患者。A2B530是基于该公司独有的技术平台开发的自体逻辑门控细胞疗法，它表达两种嵌合抗原受体（CAR），靶向CEA抗原的CAR会激活T细胞，而靶向HLA-A*02抗原的CAR会抑制T细胞活性。健康细胞由于表达HLA-A*02，不会被A2B530杀伤。而肿瘤细胞不表达HLA-A*02并且表达CEA抗原，将会激活A2B530。这一设计有望在杀伤肿瘤的同时保护健康细胞。目前该公司进行的1/2期临床试验正在进行患者招募。◇Cynata Therapeutics公司宣布，在研细胞疗法CYP-001治疗高风险急性移植物抗宿主病（aGvHD）的2期临床试验完成首例患者给药。CYP-001是该公司开发的一款由诱导多能干细胞分化而成的现货型间充质干细胞疗法。它们通过分泌生物活性分子可以起到免疫调节的作用。在治疗类固醇难治性aGvHD的1期临床试验中，CYP-001已经表现出可喜的安全性和疗效结果。美国FDA已授予其治疗aGvHD的孤儿药资格。◇Capricor Therapeutics公司公布了其主打细胞疗法CAP-1002治疗杜氏肌营养不良症（DMD）2期临床试验HOPE-2的24个月试验结果。CAP-1002是一种从健康供体心肌细胞中获取的基质细胞，具有免疫调节，抗炎症和抗纤维化的能力。试验结果显示，接受CAP-1002治疗的DMD患者24个月时与安慰剂组相比，疾病进展的速度减缓大约64%。CAP-1002同时为心脏功能提供具有临床意义的改善。◇诺华公司公布了治疗脊髓性肌萎缩症（SMA）的基因疗法Zolgensma的最新研究数据。这些数据来自比此前临床研究中入组儿童的年龄和体重更高的患者群体，其中包括曾经接受过其它药物治疗的患者。研究结果显示，几乎所有患者在接受一次性Zolgensma治疗后，达到在52周后维持或者改善运动功能里程碑。大部分曾经长期接受其它疗法治疗的患者停止使用此前接受的治疗。◇REGENXBIO公布了在研基因疗法RGX-202在4至11岁DMD患者中进行的1/2期AFFINITY DUCHENNE试验的额外中期安全性和有效性数据。试验数据显示，接受两种剂量水平的所有四例患者皆完成了在第三个月时的试验评估，分析显示其体内RGX-202微肌营养不良蛋白的表达皆有所增加，并且血清肌酐激酶（CK）水平较基线有所下降，显示该疗法具潜在临床疗效。首位接受剂量水平2治疗的12.1岁患者的数据显示，在三个月时其RGX-202微肌营养不良蛋白表达为标准对照的75.7%，且在十周时观察到患者的血清CK水平较基线降低了77%。◇Grace Science公司宣布，在研基因疗法GS-100的开放标签，1/2/3期临床试验完成首例患者给药。GS-100是一款使用重组AAV9载体，递送人类NGLY1基因的基因疗法，用于治疗NGLY1缺乏症。Grace Science公司的名字来自一名NGLY1缺乏症患者Grace。她的父亲Matt Wilsey先生与诺奖得主Carolyn Bertozzi博士联合创建了Grace Science公司，致力于开发治疗NGLY1缺乏症的基因疗法。相关阅读：当你的疾病无人知晓：致全球3亿名罕见病患者◇拜耳和BlueRock Therapeutics公司报告了双方联合开发的细胞疗法bemdaneprocel治疗帕金森病的1期临床试验最新结果。Bemdaneprocel是一款源于人类胚胎干细胞的多巴胺能神经元前体细胞疗法，它们通过手术被植入到帕金森病患者大脑中，目标是让这些细胞整合到患者大脑网络中，恢复运动和非运动功能。18个月的数据显示，bemdaneprocel表现出良好的耐受性，未发现重大安全性问题。在接受治疗12个月时停止免疫抑制后，移植细胞在18个月时仍然存活并定植于大脑中。探索性临床终点分析显示接受高剂量bemdaneprocel治疗的患者队列与低剂量组相比表现出更好的改善。2期临床试验计划在今年晚些时候开始注册患者。◇Precision BioSciences和iECURE公司宣布，已经获得英国监管机构的许可，在英国展开1/2期临床试验，评估体内基因编辑疗法ECUR-506治疗鸟氨酸转氨甲酰酶（OTC）缺乏症的效果。ECUR-506是一款体内基因编辑疗法，使用两个AAV载体递送不同载荷，一个载体递送ARCUS核酸酶在PCSK9基因位点上进行靶向基因编辑，另一个载体提供插入到这一位点的功能性OTC基因模板。这一疗法的目标是在PCSK9基因位点上通过基因编辑，持续表达OTC。大家都在看 作为药明康德旗下专注于细胞和基因疗法的CTDMO，药明生基致力于加速和变革基因和细胞治疗及其他高端治疗的开发、测试、生产和商业化。药明生基能够助力全球客户将更多创新疗法早日推向市场，造福病患。如您有相关业务需求，欢迎点击下方图片填写具体信息。▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料：[1] City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial. Retrieved March 7, 2024, from https://www.businesswire.com/news/home/20240307463963/en[2] Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency. Retrieved March 8, 2024, from https://www.businesswire.com/news/home/20240306169732/en[3] Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements. Retrieved March 8, 2024, from https://www.globenewswire.com/news-release/2024/03/06/2841232/0/en/Antion-Biosciences-announces-latest-data-and-validation-of-its-technology-platform-through-important-milestone-achievements.html[4] BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive trends at 18 months. Retrieved March 8, 2024, from https://www.globenewswire.com/news-release/2024/03/06/2841077/0/en/BlueRock-Therapeutics-phase-I-clinical-trial-for-Parkinson-s-disease-continues-to-show-positive-trends-at-18-months.html[5] GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024. Retrieved March 8, 2024, from https://www.businesswire.com/news/home/20240305810568/en[6] Grace Science, LLC Announces First Patient Treated in Phase 1/2/3 Trial of GS-100, an AAV9 Gene Therapy for NGLY1 Deficiency. Retrieved March 8, 2024, from https://www.businesswire.com/news/home/20240304132147/en[7] REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL. Retrieved March 8, 2024, from https://www.prnewswire.com/news-releases/regenxbio-announces-new-positive-initial-efficacy-data-from-affinity-duchenne-trial-302079525.html[8] Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA. Retrieved March 8, 2024, from https://www.globenewswire.com/news-release/2024/03/04/2839221/0/en/Novartis-presents-new-data-on-safety-and-efficacy-of-Zolgensma-including-maintained-and-improved-motor-milestones-in-older-and-heavier-children-with-SMA.html[9] Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. Retrieved March 8, 2024, from https://www.globenewswire.com/news-release/2024/03/06/2841425/0/en/Capricor-Therapeutics-Presents-at-2024-Muscular-Dystrophy-Association-MDA-Clinical-Scientific-Conference.html[10] First Patient Treated in Phase 2 GvHD Trial. Retrieved March 8, 2024, from https://www.prnewswire.com/news-releases/first-patient-treated-in-phase-2-gvhd-trial-302079209.html[11] Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer. Retrieved March 8, 2024, from https://www.globenewswire.com/news-release/2024/03/04/2839362/0/en/Iovance-Biotherapeutics-Announces-FDA-has-Lifted-Clinical-Hold-on-the-IOV-LUN-202-Registrational-Trial-in-Non-Small-Cell-Lung-Cancer.html免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新
细胞疗法免疫疗法临床1期基因疗法上市批准
2024-03-05
MELBOURNE, Australia, March 4, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "
CYP", "Cynata", or the
"Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).
CYP-001 is Cynata's Cymerus™ off-the-shelf iPSC[1]-derived MSC[2] product candidate for intravenous infusion, which previously generated very encouraging safety and efficacy results in a Phase 1 clinical trial in steroid-resistant aGvHD.[3] The US FDA has cleared an Investigational New Drug (IND) application for CYP-001 and granted the product Orphan Drug Designation[4] for the treatment of aGvHD.
aGvHD is a potentially life-threatening complication of bone marrow transplants or similar procedures. It arises when immune cells in the transplant (the graft) attack the recipient's tissues (the host) as "foreign". In this trial, CYP-001 is being investigated as a potential immune modulating treatment for aGvHD.
This global Phase 2 trial aims to enrol approximately 60 patients with high-risk aGvHD, who will be randomised to receive either steroids plus CYP-001, or steroids plus placebo. Additional details on the trial may be found at clinicaltrials.gov using identifier NCT05643638. The trial has been approved to commence in Australia, the USA and Turkey, and numerous clinical centres across those jurisdictions are now open for recruitment. The first patient was enrolled in the USA.
Dr Kilian Kelly, Cynata's Chief Executive Officer, said:
"The treatment of the first patient in this Phase 2 trial marks a milestone moment in the clinical development journey of CYP‑001 for aGVHD. We are continuing to open additional clinical centres, and we anticipate completion of enrolment by the end of this calendar year, with primary results available in the second half of 2025."
About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.
Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. A Phase 2 clinical trial in GvHD under a cleared US FDA IND, as well as trials of Cymerus products in osteoarthritis (Phase 3) and diabetic foot ulcers (DFU) are currently ongoing, while a trial in renal transplant is expected to commence in the near future. In addition, Cynata has also demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.
Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.
SOURCE Cynata Therapeutics
临床结果细胞疗法临床2期孤儿药临床1期
2024-02-26
MELBOURNE, Australia, Feb. 26, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU), up to the 10-week follow-up time point.
Key Highlights
The median percentage reduction in wound surface area in the active CYP-006TK group after 10 weeks was 87.6%, compared to 51.1% in the control group (n=8 per group)
Recruitment in the trial is progressing well, with 25 out of a planned 30 participants now enrolled
CYP-006TK is Cynata's Cymerus™ iPSC[1]-derived MSC[2] topical wound dressing product candidate, which comprises MSCs seeded onto a novel silicon dressing.
Due to reduced blood flow, patients with diabetes are at risk of developing non-healing wounds on the feet/lower limbs, which are also known as DFU. In addition to causing severe pain and discomfort, DFU pose a significant risk of infection, and if treatment is unsuccessful, amputation may be necessary. In this trial, CYP-006TK is being investigated as a potential treatment to promote wound healing in patients with DFU. Enrolled participants are randomised to receive either: (i) CYP‑006TK treatment for four weeks, followed by standard of care treatment for the rest of the study; or (ii) standard of care treatment throughout the study.
Follow-up visits in this trial continue until 24 weeks after the initiation of study treatment. At each follow-up visit, three-dimensional images of the study ulcer are taken using specialised camera equipment. Images are then analysed by a technician who is independent of the clinical site and blind to treatment allocation. This facilitates calculation of the wound surface area, and consequently the change in the size of the wound over time.
The analysis of the first 16 patients (n=8 per group) found that the median percentage reduction in wound surface area in the active CYP-006TK group after 10 weeks' follow-up was 87.6%, compared to 51.1% in the control group.[3] For clarity, a 100% reduction in wound surface area represents complete wound healing.
These findings are consistent with the trend observed in the results from the first six patients enrolled in this trial (n=3 per group) up to Day 28, which were released in April 2023.
In view of these very encouraging initial results, the Company confirms that the trial will continue as planned, with the aim of enrolling a total of 30 participants. Recruitment has progressed well in recent months, with 25 participants now enrolled.
Dr Jolanta Airey MD, Cynata's Chief Medical Officer, said:
"These initial results are very promising, and consistent with the previous data readout. We look forward to completing enrolment in the near future, which will take us a step closer to our objective of demonstrating safety and efficacy of CYP-006TK in DFU."
About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.
Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. A Phase 2 clinical trial in GvHD under a cleared US FDA IND, as well as trials of Cymerus products in osteoarthritis (Phase 3) and diabetic foot ulcers (DFU) are currently ongoing, while a trial in renal transplant is expected to commence in the near future. In addition, Cynata has also demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.
Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.
View original content:
SOURCE Cynata Therapeutics
Company Codes: Australia:CYP
临床结果临床1期细胞疗法临床3期临床2期
100 项与 CYP-001 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 急性移植物抗宿主病 | 临床2期 | 美国 更多 | |
| 呼吸衰竭 | 临床1期 | 澳大利亚 更多 | |
| 新型冠状病毒感染 | 临床1期 | 澳大利亚 更多 | |
| 成人呼吸窘迫综合征 | 临床1期 | 澳大利亚 更多 | |
| 类固醇难治性移植物抗宿主病 | 无进展 | 澳大利亚 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1期 | 16 | 齋窪製鏇廠鑰衊範衊簾(鏇簾積夢鹽範廠淵襯壓) = 繭窪構繭選選網顧簾簾 廠鑰繭鬱鬱鏇夢製觸夢 (選蓋觸製積窪遞蓋鑰蓋 ) 更多 | 积极 | 2020-11-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
标准版
¥16800
元/账号/年
新药情报库 ｜ 省钱又好用！
立即使用
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用